H2020Индивидуална стипендия2020–2021

OrganometRuPDT · Cancer-Cell Specific Organometallic Ru(II) Complexes as Photosensitizers in Photodynamic Therapy

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2020-03-01 → 2021-07-15
Финансиране от ЕС: 107 746 €
Участници: 1
Схема: MSCA-IF-EF-ST

Линиите свързват координатора с партньорите.

Накратко на български

Метални комплекси на рутений се тестват като фотосенсибилизатори, които активират кислорода чрез светлина за унищожаване на ракови клетки. Това помага за намаляване на страничните ефекти и преодоляване на лекарствената резистентност при някои тумори.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Cancer-Cell Specific Organometallic Ru(II) Complexes as Photosensitizers in Photodynamic Therapy

Cancer is still one of the most common and deadly diseases in the world. The current therapies usually have lots of side effects and some tumours are resistant to the most common therapeutics. Therefore, there is a need to tackle these problems and find out new strategies. Photodynamic therapy (PDT) is a promising therapy based in the combined effect of light, oxygen and a photosensitizer (PS). The non-toxic photosensitizer is excited and activated by light and this energy is transfered to oxygen, promoting singlet oxygen, extremely reactive species able to kill cells. This therapeutic mechanism allows better specificity, since only the tumoral cells will be irradiated after the injection of the PS and therefore, it will reduce side effects in patients. Moreover, it will address the acquired resistance in some tumours, improving significantly the diagnosis of some patients. The overall objective is the development of some metal complexes to be used as photosensitizers for PDT, including synthesis and characterization, and the test of these complexes in vitro first, and then in vivo.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

In this project, I plan to use cyclometalated Ru(II) polypyridyl complexes as novel photosensitizers (PSs) in photodynamic therapy (PDT) to fight cancer. Such compounds are easier to synthesise than the well-known porphyrins and have a higher lipophilicity (to better cross the cell membrane) and a bathochromic shift of the absorption (to irradiate at low energies) than the usual Ru(II) polypyridyl complexes. Furthermore, I plan to couple maleimide moieties to these complexes to directly bind cysteine-containing biomolecules (i.e. HSA) and therefore, overcome the selectivity issues observed for the typical PSs. The use of bisbenzimidazoles as ancillary ligands will allow to tune the properties of the complexes in view of having the most red-shifted absorption. Computational chemistry will be first used to design the complexes, and after the synthesis and complete characterization, biological experiments will be performed to evaluate their potential as PSs. A secondment under the supervision of Prof. Clotilde Policar will allow localizing the compounds prepared by the use of a synchrotron-based imaging technique (X-ray fluorescence) as well as single cell ICP-MS, which will help to detect the metal inside the cell and figure out the biodistribution of the complexes. The multidisciplinary scope of this work along with their innovative aspects to selectively cause death of cancerous cells, make it a ground-breaking proposal. In addition, working in one of the best universities of the world, under the supervision of Dr. Gilles Gasser and Prof. Clotilde Policar will promote my scientific career.

Оригинален текст от CORDIS (на английски).

Участници

ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARIS · ParisКоординаторФранция